The following is a summary of the Ekso Bionics Holdings, Inc. (EKSO) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Ekso Bionics reported a quarterly sales of $4.1 million in Q3 2024, a slight decrease from $4.6 million in Q3 2023.

• Gross margin for Q3 2024 was approximately 53.5%, showing a marginal improvement from 53.3% in Q3 2023.

• Operating expenses decreased to $4.8 million in Q3 2024 from $5.4 million in Q3 2023, contributing to an overall net loss decrease to $2.1 million ($0.10 per share) from $3.4 million ($0.24 per share) year-over-year.

Business Progress:

• Ekso Bionics has focused on expanding access and education about their Ekso Indego Personal device following its CMS approval.

• The company has seen strong demand in Europe with record sales levels and has expanded its international distribution network.

• Sales of Ekso's EVO exoskeleton were impacted by labor strikes, but the company continues efforts to promote its benefits.

• Ekso Bionics continues to improve operational efficiencies, particularly in supply chain and inventory management.

Opportunities:

• The approval and reimbursement of Ekso Indego Personal by CMS provides access to a new customer segment of Medicaid and Medicare patients.

• Strong international demand, especially in Europe, and continuing expansion of the distribution network present significant growth opportunities.

Risks:

• US sales have been impacted by fluctuations in procurement cycles for integrated delivery networks (IDN), with several customers delaying their capital purchases.

• Dependence on timely CMS reimbursement process, as claims have taken time with some requiring additional information for resubmittal.

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.